Panacea Biotec Share Price & Earnings Call Analysis

Financials of Panacea Biotec

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Panacea Biotec

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +115.20128.93129.19143.02150.50136.46115.72147.35163.49132.53166.70141.13165.19
Expenses +123.84134.60139.50146.58150.65142.50129.71140.35155.53159.41167.88158.92153.45
Operating Profit-8.64-5.67-10.31-3.56-0.15-6.04-13.997.007.96-26.88-1.18-17.7911.74
OPM %-7.50%-4.40%-7.98%-2.49%-0.10%-4.43%-12.09%4.75%4.87%-20.28%-0.71%-12.61%7.11%
Other Income +41.7134.4433.826.008.4613.556.547.426.3936.3016.999.105.05
Interest0.961.051.000.910.850.820.870.980.991.040.862.141.85
Depreciation9.679.519.489.319.118.818.738.688.988.428.398.348.45
Profit before tax22.4418.2113.03-7.78-1.65-2.12-17.054.764.38-0.046.56-19.176.49
Tax %13.68%169.63%15.73%6.56%33.33%-6.13%-6.86%1.05%-1.37%4,875.00%39.63%-26.92%40.06%
Net Profit +19.37-12.6810.98-8.29-2.20-1.99-15.884.714.44-1.993.96-14.013.89
EPS in Rs3.16-2.071.79-1.35-0.37-0.32-2.580.780.74-0.310.66-2.270.65

Financials of Panacea Biotec

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +510687653544593457544625661460559559606
Expenses +582643541505509591484548674558579584640
Operating Profit-72441123984-1346077-13-98-20-25-34
OPM %-14%6%17%7%14%-29%11%12%-2%-21%-4%-4%-6%
Other Income +1832870628338-2191,687154625567
Interest1501051271011011051741851814446
Depreciation71677368575443464439373534
Profit before tax-111-99-19-67-6645-178-1461,449131-8-6
Tax %2%3%10%-16%15%17%9%1%26%363%201%10%
Net Profit +-113-108-21-56-7638-194-1481,078-34-2-9-8
EPS in Rs-18.29-17.38-2.98-8.89-12.076.15-31.69-24.09175.91-5.42-0.19-1.37-1.27
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Panacea Biotec

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital6666666666666
Reserves507449426350303344193-235871837836829820
Borrowings +1,0601,1111,1059949416467428203420212223
Other Liabilities +371364317440349379449587848407378433405
Total Liabilities1,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,254
Fixed Assets +1,2761,1441,0711,001949806657609622600582567594
CWIP17215516130402324341742102128110
Investments16159775605134033
Other Assets +4796166147506025427035341,114615517592547
Total Assets1,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,254

Financials of Panacea Biotec

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +543791131118105-30107-108-422-0-27
Cash from Investing Activity +-38-3716-2655-6-35-481,2834301065
Cash from Financing Activity +-30-1-117-107-164-10191-47-1,176-18-3-3
Net Cash Flow-14-1-10-29-22612-2-10735
Free Cash Flow33085107103100-2189-119-424-71-77
CFO/OP-78%96%64%320%146%-77%-36%141%-2,235%429%-12%108%

Financials of Panacea Biotec

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days685279958471464945483747
Inventory Days375404516770651173344311296292282391
Days Payable430272318607540572463440327256244413
Cash Conversion Cycle13184278259195-328-73-8014837625
Working Capital Days-343-12627-46-96-36393-43-229-5-244
ROCE %-8%0%4%2%3%-16%5%5%-6%-10%-4%-5%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd